Apixaban During Atrial Fibrillation Catheter Ablation: Comparison to Vitamin K Antagonist Therapy
Status:
Completed
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
Study objective is to demonstrate that anticoagulation with the direct factor Xa inhibitor
apixaban is not less safe than Vitamin-K-antagonists (VKA) therapy in patients undergoing
catheter ablation of non-valvular AF in the prevention of peri-procedural complications.
The AXAFA trial will compare peri-ablational treatment with apixaban to peri-ablational
treatment wit VKA in a randomized trial of patients undergoing catheter ablation of atrial
fibrillation (AF).
Phase:
Phase 4
Details
Lead Sponsor:
Atrial Fibrillation Network German Atrial Fibrillation Network
Collaborators:
Bristol-Myers Squibb Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK) Pfizer
Treatments:
Apixaban Factor Xa Inhibitors Fluindione Phenprocoumon Vitamin K Vitamins Warfarin